After developing the chemistry for its sequencing-by-expansion nanopore technology for several years, Stratos Genomics is ready to grow its development and commercialization efforts.

The Seattle-based company is in the midst of a Series B funding round in which it hopes to raise at least $15 million by the end of March to develop a low-cost sequencing platform that combines the speed and throughput of nanopores with improved resolution and signal to noise, both for targeted and whole-genome sequencing.